P3, N=156, Not yet recruiting, Alvogen Korea

P1, N=44, Completed, University of Minnesota | Active, not recruiting --> Completed | Trial completion date: Jul 2027 --> Jun 2026

Treatment by CM in combination with SB could decrease neoplastic features in HCC group. The hepatic expression of Bcl2 was decreased, and the release of cytosolic cathepsin B was increased in the combination group. Also, the hepatic concentration of Beclin-1 decreased in the combination group and there was autophagosome accumulation in transmission electron microscope (TEM). The results indicate that the concomitant use of CM and SB may be considered a possible new therapeutic option in managing HCC by targeting the cathepsin B/Bcl2/Beclin-1 pathway.

Four-week duloxetine treatment was associated with improved sleep disturbances and reduced peripheral pro-inflammatory cytokine levels in patients with MDD. The baseline correlations between sleep parameters and pro-inflammatory cytokines, as well as the concurrent changes in these indicators following duloxetine treatment, reveal a potential relationship between sleep improvement and altered inflammatory profiles during duloxetine intervention. These preliminary findings suggest a possible link between duloxetine-related therapeutic effects on sleep and inflammatory regulation in MDD, which warrants further verification in future studies.

P=N/A, N=86, Completed, Tokat Gaziosmanpasa University | Recruiting --> Completed | Trial completion date: Jun 2026 --> Mar 2026 | Trial primary completion date: Jun 2026 --> Feb 2026

P2/3, N=139, Completed, Dow University of Health Sciences | N=47 --> 139

P2, N=336, Active, not recruiting, M.D. Anderson Cancer Center | Recruiting --> Active, not recruiting

P1, N=40, Not yet recruiting, University of Chicago

APR dose-dependently alleviated MPH-induced anxiety and depression-like behaviors, restored redox and mitochondrial homeostasis, suppressed MPH-induced neuroinflammation and neuronal apoptosis, and influenced Beclin, a key regulator of autophagosome nucleation.

These results suggest that high-dose tramadol improves cancer-associated pain but enhances the tumor volume of pancreatic ductal adenocarcinoma by decreasing anti-tumor CD8+ T lymphocytes.

P2, N=102, Not yet recruiting, VA Office of Research and Development

Contemporary consensus places somatostatin‑receptor analogues (SSAs) such as 68Ga-DOTATATE and 64Cu-DOTATATE at the center of head‑and‑neck paraganglioma (HNPGL), SDHx‑mutated disease, sporadic or hereditary HNPGLs and metastatic PPGLs, while 18F‑FDOPA is increasingly favored for adrenal pheochromocytoma (PCC); and 18F‑FDG complements both by detecting aggressive biology. MIBG now is only considered for inoperable or metastatic PPGLs under consideration for 131I‑MIBG therapy.